18F-FMAU for Imaging in Cancer Patients
Description
Brief Summary
This clinical trial studies the safety and drug distribution of the radioactive drug,
2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU
[18F-FMAU]), for imaging with positron emission tomography/computed tomography (PET/CT) in
patients with advanced cancers. A PET scan is a procedure in which a small amount of
radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed,
computerized pictures of areas inside the body where the glucose is taken up. Because cancer
cells often take up more glucose than normal cells, the pictures can be used to find cancer
cells in the body. PET/CT using the drug fluorine F 18 d-FMAU, may help find cancer and find
out how far the disease has spread.
Detailed Description
I. To determine the radiation dosimetry of 18F-FMAU in humans, confirm absence of adverse
events in humans from intravenous (i.v.) injection of 18F-FMAU for PET imaging, and
characterize the incidence of circulating metabolites of 18F-FMAU in humans.
II. To simply find out whether there is any visual uptake change of 18F-FMAU in tumors
post-therapy.
OUTLINE:
Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer
treatment. Patients may undergo 2 additional scans at one week prior to second course of
chemotherapy and after completion of cancer treatment depending on cancer type.
Phase
N/AInclusion and Exclusion Criteria
- Have been diagnosed with a malignancy/tumor/cancer, including but not limited to: brain tumor, breast cancer, lung cancer, esophageal cancer, lymphoma, or sarcoma
- Have one or more tumors visualized by conventional PET-CT, CT or magnetic resonance imaging (MRI) prior to the PET FMAU study; PET-CT should be within one week prior to 18F-FMAU
- Have undergone chemotherapy or radiation therapy within the previous one month
- Women of childbearing potential, unless they have had a negative urine beta human chorionic gonadotropin (betaHCG) within the previous 24 hours of the procedure
- Patients who have had surgery at the site of the suspected lesion within 1 month
Sites
-
California
- USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033
Powered by
SC CTSI